Kinaxo Biotechnologies GmbH is now Evotec Munich, Evotec’s Centre of Excellence for Proteomics and Oncology

In February 2011 Evotec AG acquired Kinaxo Biotechnologies GmbH, a Munich-based company offering unique market-leading proteomics applications.

The acquisition strengthens Evotec’s position as a fully integrated drug discovery partner for pharma and biotechnology companies. Kinaxo's cutting edge platform backs tailor-made therapies to increase personalized therapeutic benefits and reduce unwanted side-effect risks, enabling earlier educated decisions on drug efficacy, safety, and response in individual patients.

For more information please go to Chemical proteomics, phosphoproteomics and cellular epigenetics or contact us at proteomics@evotec.com